| Name | 5-Hydroxydecanoate sodium |
| Description | 5-Hydroxydecanoate sodium is a selective ATP-sensitive K+ (KATP) channel blocker with an IC50 of approximately 30 μM and a substrate for mitochondrial outer membrane acyl-CoA synthetase, possessing antioxidant properties. |
| In vitro | The treatment of 5-Hydroxydecanoate sodium abolished the beneficial effects of penehyclidine hydrochloride (PHC) preconditioning in anoxia/reoxygenation (A/R)‐induced injury in H9c2 cells. 5-Hydroxydecanoate sodium blocked the inhibitory effect of PHC on Ca2+ overload and ROS production and promoted the release of Cyt-C from mitochondria into cytoplasm. 5-Hydroxydecanoate sodium attenuated the anti-apoptotic effect of PHC[1]. |
| In vivo | The treatment of 5-Hydroxydecanoate sodium (100 μM) abolished the effects of ischemic preconditioning (IPC) on the contractile recovery, but 5-Hydroxydecanoate sodium did not affect its effect on the contracture, lactate production, glycogenolysis and viable tissue in rats[2]. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 1 mg/mL (4.76 mM), Sonication is recommended.
DMSO : 3.6 mg/mL (17.12 mM), Sonication is recommended.
|
| Keywords | PotassiumChannel | Potassium Channel | ATP-sensitive potassium (KATP) channels | 5-Hydroxydecanoate sodium | 5Hydroxydecanoate sodium | 5 Hydroxydecanoate sodium |
| Inhibitors Related | Minoxidil sulfate | Tannic acid | Hydrochlorothiazide | (±)-Naringenin | Tetraethylammonium bromide | Halothane | Butamben | Ursodeoxycholic acid | Cloperastine hydrochloride | Minoxidil | Nifedipine | Indapamide |
| Related Compound Libraries | Bioactive Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | Potassium Channel Targeted Library | Ion Channel Targeted Library | Anti-Cancer Compound Library |
United States
